Drug Topics March 5, 2024
Dexcom’s Stelo will be available in summer 2024.
The FDA has cleared the Dexcom Stelo Glucose Biosensor System as the first OTC continuous glucose monitor (CGM). The device is an integrated CGM intended for use in adults aged 18 years and older who do not use insulin or in those without diabetes who wish to better understand how diet and exercise affect blood glucose levels.1
For some of the 25 million individuals in the United States living with type 2 diabetes, Stelo offers those who do not use insulin—or those who do not have insurance coverage for CGM—another option to manage their disease alongside other diabetes medications.2 For adults without diabetes, Stelo’s wearable sensor measures, records, and analyzes blood glucose...
Today's Sponsors
Today's Sponsor